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Cardiometabolic risk and the MTHFR C677T variant in
children treated with second-generation
antipsychotics
AM Devlin, YF Ngai, R Ronsley and C Panagiotopoulos
Second-generation antipsychotics (SGAs) are increasingly being used to treat children with a variety of psychiatric illnesses.
Metabolic syndrome (MetS), a risk factor for cardiovascular disease, is a side-effect of SGA-treatment. We conducted a cross-
sectional study and assessed the association of the methylenetetrahydrofolate reductase (MTHFR) C677T variant with features
of MetS in SGA-treated (n¼105) and SGA–naı ¨ve (n¼112) children. We targeted the MTHFR C677T variant, because it is
associated with risk for cardiovascular disease, and features of MetS in adults without psychiatric illness. MetS in children is
based on the presence of any three of the following: waist circumference X90th percentile for age and sex; plasma triglyceride
X1.24mmoll
 1; plasma high-density lipoprotein-cholesterol p1.03mmoll
 1; systolic or diastolic blood pressure X90th
percentile for age, sex, and height; and fasting glucose X5.6mmoll
 1. We found that 15% of SGA-treated children had MetS
compared with 2% of SGA-naı ¨ve children (OR 8.113, Po0.05). No effect of the MTHFR C677T variant on psychiatric diagnosis
was observed. The MTHFR 677T allele was associated (Po0.05) with MetS (OR 5.75, 95% CI¼ 1.18–28.12) in SGA-treated
children. Models adjusted for duration of SGA treatment, ethnicity, sex, age and use of other medications revealed a positive
relationship between the MTHFR 677T allele and diastolic blood pressure Z-scores (P¼0.001) and fasting plasma glucose
(Po0.05) in SGA-treated children. These ﬁndings illustrate the high prevalence of MetS in SGA-treated children and suggest
metabolic alterations associated with the MTHFR C677T variant may have a role in the development of MetS features in SGA-
treated children.
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Introduction
Metabolic syndrome (MetS) is a side-effect associated with
use of second-generation antipsychotic (SGA) medications in
adults.
1 SGAs, also known as atypical antipsychotics, are
increasingly being used to treat children with a wide range of
psychiatric illnesses, including anxiety disorder, attention
deﬁcit hyperactivity disorder, bipolar disorder, depressive
disorder, pervasive developmental disorder, psychotic dis-
order and disruptive behavior disorder. Recent estimates
have shown that SGA prescriptions for children (14 years and
younger) in British Columbia increased 10-fold from 1997–
2007.
2 Concern is now being raised as to whether MetS
develops in children treated with SGAs and the potential long-
term consequence of this side-effect.
One classiﬁcation of MetS in children is based on the
National Cholesterol Education Program-Adult Treatment
Panel deﬁnition
3 and modiﬁed to adhere to the American
Diabetes Association deﬁnition of impaired fasting glucose of
X5.6mmoll
 1.
4 This deﬁnition includes the presence of any
three of the following features: waist circumference X90th
percentile for age and sex; plasma triglyceride (TG)
X1.24mmoll
 1; plasma high-density lipoprotein (HDL)
p1.03mmoll
 1; systolic or diastolic blood pressure X90th
percentile for age, sex, and height; and fasting glucose
X5.6mmoll
 1. We recently conducted a cross-sectional
study and found that 19% of SGA-treated children (n¼84)
had MetS compared with 0.8% of SGA-naı ¨ve children
(n¼127) (Po0.001).
5 Furthermore, a prospective study
showed that SGA-naı ¨ve children initiated on SGA treatment
andfollowedforameandurationof10.8weekshadsigniﬁcant
increases in weight, body mass index (BMI), waist circumfer-
ence, and plasma TGs relative to untreated children.
6 This
studyfurthershowedthattheeffectofSGAtreatmentonother
cardiometabolic risk factors was SGA-speciﬁc with elevated
fasting blood glucose levels observed only in children treated
witholanzapine.Themeansbywhichtodistinguishchildrenat
risk for developing MetS from those that do not and the
mechanism by which MetS develops in SGA-treated children
are not known.
Methylenetetrahydrofolate reductase (encoded by
MTHFR), is an enzyme that coverts folate, a B-vitamin, to
the metabolically active form of 5-methyltetrahydrofolate.
Homozygosity for a common variant in MTHFR, C677T,
occurs in B10% of individuals of European descent
7 and is
associated with increased risk of schizophrenia,
8 major
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8,9 Inter-
estingly, homozygosity for this variant is also associated with
increased risk of coronary heart disease,
10 and a recent
cross-sectional study found that 53% of SGA-treated adult
schizophrenia patients that carried the T-allele had MetS
compared with 23% of SGA-treated adult schizophrenia
patients with the CC genotype.
11
As a ﬁrst step towards delineating the mechanism by which
MetS develops in SGA-treated children, we assessed the
association of the MTHFR C677T variant with features of
MetS in a cross-sectional population of SGA-treated and
SGA-naı ¨ve children with mental illness. Furthermore, given
the association of the MTHFR C677T variant with psychiatric
illness in adults,
8,9 we also assessed the association of the
MTHFR C677T variant with psychiatric diagnoses in these
children.
Materials and methods
Study design and patient recruitment. A cross-sectional
study design was used to examine the relationship between
the MTHFR C677T variant and the metabolic consequences
of SGA-treatment in children. Study participants were
inpatients of either the emergency or long-stay units of the
Child and Adolescent Psychiatry Department at British
Columbia Children’s Hospital. Patients were assessed
between April 2008 and June 2011. Inclusion criteria
included: either currently receiving SGA-treatment (SGA-
treated patients) or not currently being treated with an
SGA on admission or not previously treated with an SGA
(SGA-naı ¨ve patients), and p18 years of age. Exclusion
criteria included: known cardiometabolic or endocrine
disease (including pre-existing type 1 and type 2 diabetes
mellitus), diagnosed eating disorder or current treatment
with medications known to affect metabolism (e.g.,
glucocorticoids). On admission, parents or legal guardians
provided written informed consent to participate in the study.
Children provided written assent where capable. All protocols
described were approved by the University of British
Columbia Clinical Research Ethics Board and the
Children’s and Women’s Health Centre Research Ethics
Board.
Clinical, biochemical and anthropometric measurements.
The medical records of patients were reviewed over the course
of admission and the following data were collected: socio-
demographic information (sex, age, self-reported ethnicity);
medical history, including psychiatric diagnoses, and
medications (including dose and duration); smoking habits,
family medical and psychiatric illness history. The Global
Assessment of Functioning score (range: 1–100), designed to
reﬂect overall psychological, social and occupational
functioning, and not functioning based upon physical
impairments, was determined by the attending psychiatrist
using a Multiaxial evaluation as described in the DSM-IV-TR.
12
Psychiatric diagnoses were based on independent
assessments by two Royal College of Physicians and
Surgeons (Canada)-certiﬁed psychiatrists.
Anthropometric measures included height, weight and
waist circumference. Weight was assessed in patients
wearing light clothing, pockets emptied, without shoes or
socks,and recorded tothe nearest0.1kg(TronixScale model
5002, White Plains, NY, USA). Height was assessed in
patients to the nearest 0.1cm (Seca 240 Stadiometer,
Hamburg, Germany). Waist circumference was assessed
using a non-elastic ﬂexible tape measure at the level of the
umbilicus (two measurements averaged).
13 BMI was calcu-
lated (weight (kg)/height
2 (m
2)) and then standardized for sex
and age using data from the US Centers for Disease Control
growth charts.
14 Overweight was deﬁned as BMI X85th and
o95th percentile, and obesity as BMI X95th percentile for
age and sex.
15
Diastolic and systolic blood pressure measures (average of
three readings) were collected after the child had settled into
the unit (at least 24h post admission), using a Dinamap
automated monitor and an appropriately sized cuff.
16 A blood
sample was collected by venipuncture after an overnight fast
of X8h. The following biochemical analyses were conducted
in the clinical laboratory at British Columbia Children’s
Hospital: plasma glucose, insulin, total cholesterol, low-
density lipoprotein cholesterol, HDL, TG, alanine aminotrans-
ferase and aspartate aminotransferase.
MetS was diagnosed based on the National Cholesterol
Education Program-Adult Treatment Panel deﬁnition
3 and
modiﬁed to adhere to the American Diabetes Association
deﬁnition of impaired fasting glucose.
4 A diagnosis was made
based on the presence of any three of the following features:
waist circumference X90th percentile for age and sex;
17
plasma TG X1.24mmoll
 1; plasma HDL p1.03mmoll
 1;
systolic or diastolic blood pressure X90th percentile for age,
sex, and height;
16 and fasting plasma glucose X5.6mmoll
 1.
Genomic DNA isolation and genotyping. Buccal epithelial
cells were collected by scraping the inner cheek of patients
with collection swabs (Puritan Medical Products, Guilford,
ME, USA). Genomic DNA was isolated using the QIAamp
DNA Mini Kit (Qiagen, Mississauga, Canada) and quantiﬁed
using a NanoVue Spectrophotometer (GE Healthcare,
Montreal, Canada). Genotyping of the MTHFR C677T
variant (rs1801133) was accomplished using Taqman SNP
Genotyping reagents and a 7500 Real-Time PCR System
(Applied Biosystems, Foster City, CA, USA).
Statistical analyses. Subjects were categorized as SGA-
treated and SGA-naı ¨ve. Pearson’s w
2-tests were used to
compare categorical variables between SGA-treated and
SGA-naı ¨ve patients. General linear models were used to
compare continuous variables between SGA-treated and
SGA-naı ¨ve patients. Logistic and linear regression models
were used to assess the effect of the MTHFR C677T
genotype on MetS diagnosis and characteristics of MetS.
Models were adjusted for age, sex, duration of SGA
treatment, treatment with medications known to promote
weight gain (mood stabilizers, antidepressants and ﬁrst-
generation antipsychotics), treatment with medications
known to promote weight loss (psychostimulants and
Atomoxetine) and ethnicity. Analyses were conducted using
SPSS software version 18.0 (SPSS, Chicago, IL, USA).
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Socio-demographic, anthropometric and metabolic
characteristics of study population. In total, 261
subjects consented to the study; 44 subjects were excluded
due to pre-existing cardiometabolic disease, endocrine
abnormalities, diagnosed eating disorders and/or treatment
with glucocorticoids; and 8 subjects did not have DNA
collected. The socio-demographic and characteristics of the
subjects are given in Table 1. There were no differences in
age, sex, ethnicity, smoking or global assessment of
functioning scores between SGA-treated and SGA-naı ¨ve
children. The majority of our study population was of
European-descent (74% SGA-treated and 71% SGA-naı ¨ve).
The median duration of SGA-treatment was 6 months
(ranging from 0.25 to 76 months). The majority of SGA-
treated children were receiving quetiapine (46.7%) or
risperidone (43.8 %) (Table 1). Children were also often
treated with other medications including antidepressants,
psychostimulants, mood stabilizers, atomoxetine and ﬁrst
generation antipsychotics, which were controlled for in our
logistic and linear regression models.
Similar to our previous ﬁndings, SGA-treated children had
higher (Po0.05) zBMI with 30.1% of SGA-treated patients
having a BMI X95th percentile compared with 17% of SGA-
naı ¨ve patients (Table 2). SGA-treated children had a higher
(P¼0.001)prevalenceofMetS(15.6%ofpatients)thanSGA-
naı ¨ve children (2.1% of patients), with an odds ratio of 8.11
(95% CI¼1.41–46.77) (Table 2). We further assessed
characteristics of the MetS and found that SGA-treated
children had higher (Po0.05) systolic blood pressure
Z-scores; a higher (Po0.05) prevalence of children with
blood pressure X90th percentile for age, sex and height;
a n dah i g h e r( Po0.05) prevalence of children with waist
circumference X90th percentile for age and sex than SGA-
naı ¨ve children. SGA-treated children also had higher
fasting plasma glucose (P¼ 0.005), insulin (Po0.043),
total cholesterol (Po0.01) and low-density lipoprotein
(Po0.05) levels compared with the SGA-naı ¨vep a t i e n t s
(Table 2).
Table 2 Cardiometabolic characteristics of the study population
Characteristic SGA-treated (n¼105) SGA-naı ¨ve (n¼112)P value
MetS,n (%) 15 (15.6) 2 (2.1) 0.001
zBMI, mean (s.d.) 1.013 (0.979) 0.731 (0.973) 0.038
aobese, n (%) 31 (30.1) 18 (17.0)
overweight,n (%) 23 (22.3) 24 (22.6)
normal, n (%) 49 (47.6) 64 (60.4)
WC X90
thpercentile, n (%) 39 (37.1) 28 (25.0) 0.037
WC (cm), mean (s.d.) 78.9 (15.0) 77.3 (17.5) 0.488
BP X90th percentile, n (%) 25 (25.0) 15 (14.4) 0.042
SBP Z-score, mean (s.d.) 0.445 (1.07) 0.112 (0.90) 0.016
DBP Z-score, mean (s.d.) 0.409 (0.72) 0.412 (0.67) 0.976
Impaired fasting glucose (X5.6mmoll
 1), n(%) 6 (5.7) 3 (2.7) 0.218
Fasting glucose (mmoll
 1), mean (s.d.) 4.92 (0.34) 4.78 (0.34) 0.005
Fasting insulin (pmoll
 1), mean (s.d.) 61.31 (40.76) 50.94 (26.02) 0.043
Elevated TG (X1.24mmoll
 1), n (%) 24 (22.9) 19 (17.0) 0.179
TG (mmoll
 1), mean (s.d.) 1.09 (0.67) 0.96 (0.41) 0.100
Low HDL (p1.03mmoll
 1), n (%) 23 (21.9) 15 (13.4) 0.071
HDL (mmoll
 1), mean (s.d.) 1.32 (0.39) 1.30 (0.30) 0.716
LDL (mmoll
 1), mean (s.d.) 2.76 (0.96) 2.45 (0.72) 0.017
Total cholesterol (mmoll
 1), mean (s.d.) 4.54 (1.05) 4.19 (0.84) 0.009
AST (U/L), mean (s.d.) 32.57 (12.24) 30.12 (10.22) 0.138
ALT (U/L), mean (s.d.) 22.82 (16.12) 20.74 (13.66) 0.339
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; BP, blood pressure; DBP, diastolic blood pressure; HDL,
high-density lipoprotein cholesterol; LDL, low-density lipoprotein cholesterol; MetS, metabolic syndrome; SBP, systolic blood pressure; SGA, second-generation
antipsychotic; TG, triglyceride; WC, waist circumference.
The effect of SGA-treatment was analyzed by unadjusted Pearson’s w
2-tests for categorical variables and unadjusted general linear models for continuous variables.
aObese¼BMI X95
th percentile; overweight¼BMI X85th percentile; and normal¼BMIo85
th percentile.






Age(years),mean(s.d.) 12.58 (3.14) 13.19 (2.86) 0.133
Male sex, n (%) 70 (66.7) 64 (57.1) 0.096
Ethnicity, n (%) 0.890
European 77 (74.0) 79 (70.5)
Asian 9 (8.7) 9 (8.0)
Aboriginal 3 (2.9) 4 (3.6)
South Asian 3 (2.9) 3 (2.7)
African/Caribbean 7 (10.7) 12 (10.6)
Hispanic 5 (4.8) 4 (3.6)
Other 0 (0) 1 (0.9)
Smoker, n (%) 15 (15.0) 21 (19.1) 0.274
GAF score, mean (s.d.) 54.05 (10.83) 55.13 (8.68) 0.436




Quetiapine, n (%) 49 (46.7)
Risperidone, n (%) 46 (43.8)
Aripiprazole, n (%) 5 (4.8)
Olanzapine,n (%) 4 (3.8)
Ziprasidone, n (%) 1 (1.0)
Abbreviations: GAF, global assessment of functioning; NA, not applicable;
SGA, second-generation antipsychotic.
Differences between SGA-treated and SGA-naı ¨ve patients were assessed by
unadjusted Pearson’s w
2-tests for categorical variables and by general linear
models for continuous variables.
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diagnosis. The MTHFR 677TT genotype occurs at a
frequency of B10–12% in populations of European-
decent.
7,18 In this study, we found 17 out of 209 (8.1%) of
our study patients (8 out of 99 SGA-treated and 9 out of 110
SGA-naı ¨ve) had the MTHFR 677TT genotype with a 27% T-
allele frequency. Given the association of the MTHFR C677T
variant with psychiatric illness in adults,
8,9 we assessed the
association of the MTHFR C677T variant with psychiatric
diagnoses in our pediatric study patients. The patients in our
study had a wide-range of psychiatric diagnoses. As such,
patients with multiple DSM-IV Axis I diagnoses were assessed
under multiple diagnostic categories. Interestingly, we found
no association between the MTHFR C677T variant and
psychiatric diagnoses in our patient population (Table 3).
Association of the MTHFR C677T variant and MetS
characteristics. A higher prevalence of MetS has been
previously reported in SGA-treated adults with schizophrenia
carrying the T-allele of the MTHFR C677T variant than those
with the CC genotype.
11 As such, we investigated the
association of the MTHFR C677T variant with MetS and
MetS components in the SGA-treated children in our study
population. The SGA-naı ¨ve patients were not included in
this analysis, because of the low prevalence of MetS
diagnosis (2%) in this group. We found that SGA-treated
patients carrying the T-allele had a higher prevalence
(Po0.05) of MetS, higher (P¼0.005) diastolic blood
pressure Z-scores, and higher (Po0.05) fasting plasma
glucose compared with patients with the CC genotype
(Table 4). Further analyses using logistic regression
models adjusted for duration of SGA-treatment, ethnicity,
sex, age and use of other medications revealed that the T-
allele of the MTHFR C677T variant was associated with a
greater (P¼0.03) chance of having MetS (odds ratio ¼
5.75, 95% CI¼ 1.18–28.12).
Table 3 MTHFR C677T variant and pediatric psychiatric diagnoses
Diagnosis MTHFR C677T Genotype
CC (n¼113) CT and TT (n ¼ 96)P value
Psychotic disorder, n (%) 11 (9.7) 8 (8.3) 0.812
Depressive disorder, n (%) 29 (25.7) 22 (22.9) 0.448
Bipolar disorder, n (%) 55 (48.7) 49 (51.0) 0.174
Anxiety disorder, n (%) 14 (12.4) 16 (16.7) 0.884
ADHD, n (%) 36 (31.9) 26 (27.1) 0.707
Disruptive behavior disorder, n (%) 14 (12.4) 11 (11.5) 0.672
Pervasive developmental disorder, n (%) 7 (6.2) 14 (14.6) 0.056
Substance-related disorder, n (%) 11 (9.7) 9 (9.4) 0.930
Abbreviations: ADHD, attention deﬁcit hyperactivity disorder; MTHFR, methylenetetrahydrofolate reductase.
The effect of the MTHFR C677T variant on pediatric psychiatric diagnoses was analyzed by Pearson’s w
2-tests.
Table 4 Cardiometabolic characteristics of SGA-treated patients and MTHFR C677T genotype
Characteristic MTHFR C677T genotype
CC (n¼54) CT and TT (n¼45)P value
MetS,n (%) 4 (7.8) 10 (25.0) 0.039
WC X90
thpercentile, n (%) 16 (29.6) 20 (44.4) 0.146
WC (cm), mean (s.d.) 76.3 (13.4) 80.5 (15.2) 0.170
BMI Z-score, mean (s.d.) 0.897 (0.885) 1.111 (1.084) 0.285
BP X90th percentile, n (%) 9 (17.3) 13 (31.0) 0.145
SBP Z-score, mean (s.d.) 0.278 (1.08) 0.562 (1.07) 0.205
DBP Z-score, mean (s.d.) 0.195 (0.755) 0.604 (0.596) 0.005
Fasting glucose X5.6mmoll, n (%) 2 (3.7) 3 (6.7) 0.657
Fasting glucose (mmoll
 1), mean (s.d.) 4.85 (0.30) 5.01 (0.37) 0.028
Fasting insulin (pmoll
 1), mean (s.d.) 56.27 (37.96) 65.00 (43.06) 0.318
TG X1.24mmoll
 1, n (%) 10 (18.5) 13 (28.9) 0.242
TG (mmoll
 1), mean (s.d.) 1.10 (0.71) 1.09 (0.57) 0.896
HDL p1.03mmoll
 1, n (%) 12 (22.2) 10 (22.2) 1.000
HDL(mmoll
 1), mean (s.d.) 1.35 (0.36) 1.27 (0.42) 0.304
LDL (mmoll
 1), mean (s.d.) 2.71 (0.92) 2.91 (1.00) 0.331
Total cholesterol (mmoll
 1), mean (s.d.) 4.58 (1.03) 4.62 (1.06) 0.850
Abbreviations: BMI, body mass index; BP, blood pressure; DBP, diastolic blood pressure; HDL, high-density lipoprotein cholesterol; LDL, low-density lipoprotein
cholesterol; MetS, metabolic syndrome; MTHFR, methylenetetrahydrofolate reductase; SBP, systolic blood pressure; SGA, second-generation antipsychotic; TG,
triglyceride; WC, waist circumference.
The effect of the MTHFR C677T variant on cardiometabolic characteristics was analyzed by unadjusted Pearson’s w
2-tests for categorical variables and unadjusted
general linear models for continuous variables.
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treatment, ethnicity, sex, age and use of other medications
were used to assess the relationship of the MTHFR C677T
genotype with individual characteristics of MetS in SGA-
treated children. The T-allele of the MTHFR C677T variant
was positively associated with diastolic blood pressure Z-
scores (b-coefﬁcient¼0.313, P¼0.001) and fasting glucose
levels (b-coefﬁcient¼0.256, Po0.05) (Table 5). No relation-
ships were observed between anthropometric measures
(waist circumference, BMI Z-scores) and plasma HDL and
TG levels (Table 5).
Discussion
The goal of this study was to determine if the MTHFR C677T
variant is associated with psychiatric diagnoses and char-
acteristics of the MetS in a cross-sectional population of SGA-
treatedchildrenandSGA-naı ¨vechildrenrecruitedthroughour
inpatient psychiatric units. There are three main ﬁndings of
this study. As we predicted, we found that MetS is more
prevalent in SGA-treated children compared with SGA-naı ¨ve
children. Elevated blood pressure and elevated fasting
glucose, both components of the MetS, are also more
prevalent in SGA-treated children compared with SGA-naı ¨ve
children. Interestingly, we found that the MTHFR C677T
variant was associated with increased prevalence of MetS
in SGA-treated children, with the T-allele associated with
signiﬁcantlyhigherbloodpressureandhigherfastingplasma
glucose levels than children with the MTHFR 677CC
genotype.
This current study conﬁrms the higher prevalence of MetS
in a second, distinct population of SGA-treated children and is
similar to the ﬁndings of our initial study that showed MetS is
more prevalent in SGA-treated children than in SGA-naı ¨ve
children.
5 Studies in adults have reported MetS in 37.3% of
SGA-treated patients,
1 which is higher than the prevalence
rates of 15.6% in SGA-treated children (median duration 6
months) in the current study and 19% in SGA-treated children
(median treatment duration of 14 months) in our prior study.
5
The difference in prevalence rates between adults and
children is likely because MetS is not as common in children
as it is in adults.
When we further investigated differences in the compo-
nents of the MetS between SGA-treated and SGA-naive
children, we found higher waist circumference, blood pres-
sure, and fasting plasma glucose levels but no differences in
plasma TGs or HDL in the SGA-treated children compared
with SGA-naı ¨ve children. A study in children treated with
risperidone and followed for 8 weeks found signiﬁcant
increases in body weight, BMI Z-scores and waist circumfer-
ence,butnodifferencesinplasmalipidsorglucose.
19Another
study showed that children treated with olanzapine and
risperidone andfollowedfor4weekshadsigniﬁcantincreases
in BMI, but only those treated with olanzapine had elevations
in blood pressure and diagnosis of MetS from baseline
20
suggesting the type of SGA-treatment may inﬂuence the
development of MetS characteristics. However, in our current
study only 3.8% of the children were treated with olanzapine,
with the majority treated with either risperidone (43.8%) or
quetiapine (46.7%), similar to our prior study.
5 Furthermore,
a prospective study showed signiﬁcant increases in BMI
Z-scores, waist circumference, fat mass and TGs in children
initiated on treatment with olanzapine, risperidone or quetia-
pine and followed for a mean duration of 10.8 weeks.
6
However, only olanzapine treatment in this study was
associated withsigniﬁcantelevations infasting bloodglucose.
Taken together, these studies suggest that both the type of
SGA treatment and duration of treatment may inﬂuence the
development of MetS characteristics.
Surprisingly, we found no association of the MTHFR 677T
allele with psychiatric diagnoses. Studies in adults have
reported an association between the MTHFR 677TT geno-
type and bipolar disorder, major depressive disorder and
schizophrenia.
8,9 Furthermore, we recently found greater
depressed mood in pregnant women that were homozygous
for the MTHFR C677T variant, an effect that was not
inﬂuenced by serotonin reuptake inhibitor treatment.
21 In the
current study we did not assess the effects of the MTHFR
677TT genotype on psychiatric diagnosis because of the low
frequency of the genotype in our population. Further larger
studies are required to deﬁnitely assess the effects of the
MTHFR 677TT genotype on psychiatric diagnosis in children.
Similar to what has been reported in studies in SGA-treated
adultswithschizophrenia,
11wefoundasigniﬁcantassociation
of the T-allele of the MTHFR C677T variant with MetS and
also observed a positive association of the T-allele with
diastolic blood pressure Z-scores and fasting plasma glucose
levels. However, others have reported no association of the
MTHFR C677T variant with MetS in SGA-treated adults, but
did report an association between the MTHFR A1298C
variant and MetS.
22 Further, this same group investigated
the inﬂuence of the MTHFR C677T and A1298C variants on
the development of MetS characteristics within the ﬁrst 3
months of SGA-treatment and reported that only the MTHFR
1298CC genotype was associated with greater weight gain,
fasting plasma glucose and plasma glucose concentrations at
120min during an oral glucose tolerance test.
23 However,
another study reported no effect of the MTHFR A1298C
variant on MetS in SGA-treated adults.
11 We also assessed
t h ee f f e c to ft h eMTHFR A1298C variant in our population,
but found no association with MetS or its components. This
may in part be because of the low frequency of the MTHFR
Table 5 Relationship between the MTHFR C677T variant and cardiometabolic
characteristics in SGA-treated children
Characteristic Standardized b-coefﬁcient P value
BMI Z-score 0.095 0.357
WC 0.150 0.090
SBP Z-score 0.172 0.068
DBP Z-score 0.313 0.001
Fasting glucose 0.256 0.022
Fasting insulin 0.120 0.259
Triglyceride 0.003 0.978
HDL  0.123 0.249
Abbreviations: BMI, body mass index; DBP, diastolic blood pressure; HDL,
high-density lipoprotein cholesterol; SBP, systolic blood pressure; SGA,
second-generation antipsychotic; WC, waist circumference.
Adjusted for duration of SGA treatment, ethnicity, sex, age and use of other
medications.
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data).
Little is known regarding the mechanisms by which the
MTHFR C677T variant may be associated with MetS in SGA-
treated children. The MTHFR enzyme is required for the
metabolism of folate and the production of 5-methyltetrahy-
drofolate, which is used in the remethylation of homocysteine
to methionine, an important step in the generation of methyl
groups. Homozygosity for the MTHFR C677T variant is
associated with a thermolabile form of the enzyme,
7 elevated
plasma total homocysteine levels,
7,18 and global changes in
DNA methylation.
24–26 Given the metabolic tie of MTHFR to
DNA methylation, an epigenetic process important for the
regulation of gene expression, the mechanism by which the
MTHFR677TalleleisassociatedwithdevelopmentofMetSin
SGA-treated children may be related to changes in DNA
methylation and a gene expression proﬁle that favours
development of MetS characteristics.
Prior studies in adult populations, with no underlying
psychiatric diagnoses or SGA-treatment, have shown the
MTHFR C677Tvariant isassociated with anincreased risk for
cardiovascular disease,
10 an effect attributed to elevations in
plasma total homocysteine
27 and the vascular metabolism of
folates.
28 In the current study, we were not able to quantify
plasma total homocysteine levels. We also found signiﬁcant
associations of the T-allele of the MTHFR C677T variant with
diastolic blood pressure Z-scores and fasting plasma glucose
levels in SGA-treated children. Interestingly several studies in
adult populations have reported associations of the MTHFR
C677T variant with blood pressure.
29–31 A meta-analysis
showed that the MTHFR C677T variant is associated with
increased risk for hypertension.
29 Furthermore, recent gen-
ome-wide association studies have identiﬁed the MTHFR loci
to be associated with systolic and diastolic blood pres-
sure.
30,31 Therefore, the MTHFR C677T variant may have a
strong inﬂuence on blood pressure in SGA-treated children
and contribute to the association of the T-allele with MetS
diagnosis.
Overall, this study is the ﬁrst to demonstrate that the
T-allele of the MTHFR C677T variant is associated with MetS
and its characteristics of elevated blood pressure and higher
fasting plasma glucose levels in SGA-treated children. The
mechanism by which the MTHFR 677T allele may contribute
to the development of MetS and its components is not known.
Further studies are required to investigate potential mechan-
isms and to determine whether SGA-treatment produces
disturbances in methyl metabolites and epigenetic changes
in gene expression, especially those regulated by DNA
methylation.
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